Hernández-Blanquisett Abraham, Quintero-Carreño Valeria, Martínez-Ávila María Cristina, Porto María, Manzur-Barbur María Carolina, Buendía Emiro
Cancer Institute, Hospital Serena del Mar, Cartagena, Colombia.
Clinical Oncology, Hospital Serena del Mar, Cartagena, Colombia.
Oncol Rev. 2024 Jan 18;17:11364. doi: 10.3389/or.2023.11364. eCollection 2023.
Pancreatic cancer is one of the most lethal neoplasms worldwide; it is aggressive in nature and has a poor prognosis. The overall survival rate for pancreatic cancer is low. Most patients present non-specific symptoms in the advanced stages, which generally leads to late diagnosis, at which point there is no option for curative surgery. The treatment of metastatic pancreatic cancer includes systemic therapy, in some cases radiotherapy, and more recently, molecular targeted therapies, which can positively impact cancer control and improve quality of life. This review provides an overview of the molecular landscape of pancreatic cancer based on the most recent literature, as well as current treatment options for patients with metastatic pancreatic cancer.
胰腺癌是全球最致命的肿瘤之一;其本质上具有侵袭性,预后较差。胰腺癌的总体生存率较低。大多数患者在晚期出现非特异性症状,这通常导致诊断延迟,此时已无法进行根治性手术。转移性胰腺癌的治疗包括全身治疗,在某些情况下还包括放疗,以及最近出现的分子靶向治疗,这些治疗可以对癌症控制产生积极影响并提高生活质量。本综述基于最新文献概述了胰腺癌的分子格局,以及转移性胰腺癌患者的当前治疗选择。